Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation

Osteoarthritis and Cartilage

Volumn 17, Issue 2, 2009, Pages 235-243

  Akasaki, Y ^a   Matsuda, S ^a   Nakayama, K ^a   Fukagawa, S ^a   Miura, H ^a   Iwamoto, Y ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cartilage degradation; Osteoarthritis; Statin; Synovial inflammation

Indexed keywords

CD68 ANTIGEN; COLLAGENASE 3; COMPACTIN; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; ARTICULAR CARTILAGE; BIOCHEMISTRY; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KNEE OSTEOARTHRITIS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SYNOVIOCYTE; SYNOVITIS; TREATMENT DURATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CCL2; CHONDROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1BETA; LOVASTATIN; MATRIX METALLOPROTEINASE 3; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 59249095198     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.06.012     Document Type: Article

References (46)

1. Ge Z., Hu Y., Heng B.C., Yang Z., Ouyang H., Lee E.H., et al. Osteoarthritis and therapy. Arthritis Rheum 55 3 (2006 Jun 15) 493-500
2. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 38 (1995) 1541-1546
3. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 12 (2003 Dec) 1145-1155
4. Loeuille D., Chary-Valckenaere I., Champigneulle J., Rat A.C., Toussaint F., Pinzano-Watrin A., et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum 52 11 (2005 Nov) 3492-3501
5. Pelletier J.P., Martel-Pelletier J., and Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 44 6 (2001 Jun) 1237-1247
6. Pelletier J.P., Martel-Pelletier J., Ghandur-Mnaymneh L., Howell D.S., and Woessner J.F. Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 28 5 (1985 May) 554-561
7. Revell P.A., Mayston V., Lalor P., and Mapp P. The synovial membrane in osteoarthritis: a histological study including the characterisation of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodies. Ann Rheum Dis 47 4 (1988 Apr) 300-307
8. Haraoui B., Pelletier J.P., Cloutier J.M., Faure M.P., and Martel-Pelletier J. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum 34 2 (1991 Feb) 153-163
9. Haywood L., McWilliams D.F., Pearson C.I., Gill S.E., Ganesan A., Wilson D., et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 48 8 (2003 Aug) 2173-2177
10. Benito M.J., Veale D.J., FitzGerald O., van den Berg W.B., and Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 64 9 (2005 Sep) 1263-1267
11. Smith M.D., Triantafillou S., Parker A., Youssef P.P., and Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24 2 (1997 Feb) 365-371
12. van Valburg A.A., Wenting M.J., Beekman B., Te Koppele J.M., Lafeber F.P., and Bijlsma J.W. Degenerated human articular cartilage at autopsy represents preclinical osteoarthritic cartilage: comparison with clinically defined osteoarthritic cartilage. J Rheumatol 24 2 (1997 Feb) 358-364
13. Mehraban F., Lark M.W., Ahmed F.N., Xu F., and Moskowitz R.W. Increased secretion and activity of matrix metalloproteinase-3 in synovial tissues and chondrocytes from experimental osteoarthritis. Osteoarthritis Cartilage 6 4 (1998 Jul) 286-294
14. Blom A.B., van Lent P.L., Libregts S., Holthuysen A.E., van der Kraan P.M., van Rooijen N., et al. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum 56 1 (2007 Jan) 147-157
15. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., and Woessner J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84 2 (1989 Aug) 678-685
16. Bondeson J., Wainwright S.D., Lauder S., Amos N., and Hughes C.E. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 8 6 (2006) R187
17. Farahat M.N., Yanni G., Poston R., and Panayi G.S. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52 12 (1993 Dec) 870-875
18. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 20 (1995 Nov 16) 1301-1307
19. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Faergeman O., Faergeman G., et al. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004 Oct 5 3 (1994) 81-87
20. Friesen J.A., and Rodwell V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 5 11 (2004) 248 [Epub 2004 Nov 1]
21. Abeles A.M., and Pillinger M.H. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?. Arthritis Rheum 54 2 (2006 Feb) 393-407
22. Arnaud C., Braunersreuther V., and Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15 6 (2005 Aug) 202-206
23. Zhao S., Li Q., Liu L., Xu Z., and Xiao J. Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 344 1-2 (2004 Jun) 195-200
24. Waehre T., Yndestad A., Smith C., Haug T., Tunheim S.H., Gullestad L., et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109 16 (2004 Apr 27) 1966-1972 [Epub 2004 Mar 29]
25. Luan Z., Chase A.J., and Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23 5 (2003 May 1) 769-775
26. Lazzerini P.E., Capecchi P.L., Nerucci F., Fioravanti A., Chellini F., Piccini M., et al. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 63 7 (2004 Jul) 867-869
27. Romano M., Diomede L., Sironi M., Massimiliano L., Sottocorno M., Polentarutti N., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80 7 (2000 Jul) 1095-1100
28. Sparrow C.P., Burton C.A., Hernandez M., Mundt S., Hassing H., Patel S., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 1 (2001 Jan) 115-121
29. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170 3 (2003 Feb 1) 1524-1530
30. Jo H., Ahn H.J., Kim E.M., Kim H.J., Seong S.C., Lee I., et al. Effects of dehydroepiandrosterone on articular cartilage during the development of osteoarthritis. Arthritis Rheum 50 8 (2004 Aug) 2531-2538
31. Yudoh K., Shishido K., Murayama H., Yano M., Matsubayashi K., Takada H., et al. Water-soluble C60 fullerene prevents degeneration of articular cartilage in osteoarthritis via down-regulation of chondrocyte catabolic activity and inhibition of cartilage degeneration during disease development. Arthritis Rheum 56 10 (2007 Oct) 3307-3318
32. Brown M.S., Faust J.R., Goldstein J.L., Kaneko I., and Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253 4 (1978 Feb 25) 1121-1128
33. Petty R.D., Sutherland L.A., Hunter E.M., and Cree I.A. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10 1 (1995 Jan-Feb) 29-34
34. Shikhman A.R., Amiel D., D'Lima D., Hwang S.B., Hu C., Xu A., et al. Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis 64 1 (2005 Jan) 89-94
35. Mankin H.J., Dorfman H., Lippiello L., and Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 53 3 (1971 Apr) 523-537
36. Cunnane G., Bjork L., Ulfgren A.K., Lindblad S., FitzGerald O., Bresnihan B., et al. Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. Ann Rheum Dis 58 8 (1999 Aug) 493-499
37. Yoshimi T., Kikuchi T., Obara T., Yamaguchi T., Sakakibara Y., Itoh H., et al. Effects of high-molecular-weight sodium hyaluronate on experimental osteoarthrosis induced by the resection of rabbit anterior cruciate ligament. Clin Orthop Relat Res 298 (1994 Jan) 296-304
38. Hulmes D.J., Marsden M.E., Strachan R.K., Harvey R.E., McInnes N., and Gardner D.L. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthritis Cartilage 12 3 (2004 Mar) 232-238
39. Takahashi K., Goomer R.S., Harwood F., Kubo T., Hirasawa Y., and Amiel D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta(IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 7 2 (1999 Mar) 182-190
40. Yuan G.H., Masuko-Hongo K., Kato T., and Nishioka K. Immunologic intervention in the pathogenesis of osteoarthritis. Arthritis Rheum 48 3 (2003 Mar) 602-611
41. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 11 (2001 Nov) 1712-1719
42. Wang I.K., Lin-Shiau S.Y., and Lin J.K. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 59 3 (2000 Sep) 245-254
43. Thunyakitpisal P.D., and Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 94 4 (2004 Apr) 403-409
44. Porter K.E., Turner N.A., O'Regan D.J., and Ball S.G. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64 3 (2004 Dec 1) 507-515
45. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 11 (1998 Nov) 1671-1678
46. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 13 (2003 Apr 2) 1681-1690